ENDOCRINE TREATMENT OPTIONS FOR ADVANCED BREAST CANCER — THE ROLE OF FULVESTRANT

ENDOCRINE TREATMENT OPTIONS FOR ADVANCED BREAST CANCER — THE ROLE OF FULVESTRANT

For many years, tamoxifen has been the _gold standard_ amongst anti-oestrogen therapies for breast cancer. However, the selective aro- matase inhibitors (AIs), anastrozole, letrozole and exemestane, have demonstrated advantages over tamoxifen as first-line treatments for advanced disease. Anastrozol...

Full description

Bibliographic Details
Main Authors:	J.F.R. Robertson, S.E. Come, S.E. Jones, L. Beex, M. Kaufmann, A. Makris, J.W.R. Nortier, K. Possinger, L.-E. Rutqvist
Format:	Article
Language:	Russian
Published:	ABV-press 2014-09-01
Series:	Opuholi Ženskoj Reproduktivnoj Sistemy
Online Access:	https://ojrs.abvpress.ru/ojrs/article/view/335

Similar Items

Fulvestrant in endocrine therapy of recurrent and metastatic breast cancer
by: L Yu Vladimirova
Published: (2016-12-01)

A comparison of fulvestrant plus a targeted agent with fulvestrant alone in hormone receptor-positive advanced breast cancer that progressed on prior endocrine therapy: a meta-analysis
by: Xu L, et al.
Published: (2018-11-01)

Clinical activity of fulvestrant in metastatic breast cancer previously treated with endocrine therapy and/or chemotherapy
by: Mi Hwa Heo, et al.
Published: (2019-09-01)

The use of fulvestrant, a parenteral endocrine agent, in intestinal obstruction due to metastatic lobular breast carcinoma
by: Rampaul Rajendra Singh, et al.
Published: (2008-12-01)

Fulvestrant in treatment for metastatic breast cancer
by: L. Yu. Vladimirova, et al.
Published: (2019-12-01)

Fulvestrant in advanced breast cancer: evidence to date and place in therapy
by: Katalin Boér
Published: (2017-07-01)

Comparative efficacy of different targeted therapies plus fulvestrant for advanced breast cancer following progression on prior endocrine therapy: a network meta-analysis
by: Zhang T, et al.
Published: (2018-11-01)

Fulvestrant vne klinicheskikhissledovaniy (opyt otdeleniya khimioterapii)
by: E K Voznyy,, et al.
Published: (2010-12-01)

Low-Dose Fulvestrant Maintained Long-Term Complete Remission after Poor Response to Previous Endocrine Therapies in a Patient with Advanced Breast Cancer
by: H. Hawle, et al.
Published: (2010-04-01)

Fulvestrant in hormone-positive advanced breast cancer: Real-world outcome
by: Indhuja Muthiah Vaikundaraja, et al.
Published: (2020-01-01)

Approaches to interpret the outcomes of a network meta-analysis on comparative efficacy of different targeted therapies plus fulvestrant for advanced breast cancer following progression on prior endocrine therapy
by: Jayaraj R, et al.
Published: (2019-04-01)

Fulvestrant: One step at a time?
by: P Harish, et al.
Published: (2020-01-01)

Fulvestrant v sovremennoy terapii rasprostranennogo raka molochnoy zhelezy: farmakoekonomicheskoe obosnovanie
by: V P Komarova, et al.
Published: (2007-09-01)

Fulvestrant - endokrinnaya terapiya rasshirennogo spektra deystviya
by: A A Meshcheryakov
Published: (2012-09-01)

Fulvestrant in the fight against ER-positive advanced breast cancer; lone soldier or an important partner?
by: Ashish Singh
Published: (2020-01-01)

SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer
by: Carla L. Alves, et al.
Published: (2018-06-01)

Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer
by: Sunil Pancholi, et al.
Published: (2019-12-01)

Clinical benefit of fulvestrant monotherapy in the multimodal treatment of hormone receptor and HER2 positive advanced breast cancer: a case series
by: Rusz O, et al.
Published: (2018-09-01)

Correction to: Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer
by: Sunil Pancholi, et al.
Published: (2020-01-01)

Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study
by: Peter A. Fasching, et al.
Published: (2020-12-01)

Clinical and genetic risk factors for Fulvestrant treatment in post-menopause ER-positive advanced breast cancer patients
by: Jingyu Liu, et al.
Published: (2019-01-01)

Effect of the prenatal action of fulvestrant on the ovaries of the offspring of laboratory mice
by: Rimma T. Sulaymanova
Published: (2021-12-01)

Editorial: Advances in the Endocrine Role of the Skeleton
by: Roberto Baldelli, et al.
Published: (2020-10-01)

Clinical utility of fulvestrant in the treatment of breast cancer: a report on the emerging clinical evidence
by: Rocca A, et al.
Published: (2018-08-01)

Fulvestrant in the treatment of luminal metastatic breast cancer: the balance of effectiveness and safety
by: I. A. Koroleva, et al.
Published: (2020-07-01)

Endoxifen and fulvestrant regulate estrogen-receptor α and related DEADbox proteins
by: Jasmin Asberger, et al.
Published: (2020-12-01)

Fulvestrant in Combination with CDK4/6 Inhibitors for HER2- Metastatic Breast Cancers: Current Perspectives
by: Iorfida M, et al.
Published: (2020-03-01)

Palbociclib and Fulvestrant Act in Synergy to Modulate Central Carbon Metabolism in Breast Cancer Cells
by: Benedikt Warth, et al.
Published: (2019-01-01)

Effect of Berry Extracts and Bioactive Compounds on Fulvestrant (ICI 182,780) Sensitive and Resistant Cell Lines
by: Denzel R. Woode, et al.
Published: (2012-01-01)

The Exposure of Breast Cancer Cells to Fulvestrant and Tamoxifen Modulates Cell Migration Differently
by: Dionysia Lymperatou, et al.
Published: (2013-01-01)

Differential Pulse Voltammetric Determination of Fulvestrant in Pharmaceutical Dosage Forms and Serum Samples
by: Dilek Kul, et al.
Published: (2011-01-01)

Fulvestrant in the treatment of hormone receptor‐positive/human epidermal growth factor receptor 2‐negative advanced breast cancer: A review
by: Junjie Li, et al.
Published: (2019-05-01)

Prognostic value of monitoring tumour markers CA 15-3 and CEA during fulvestrant treatment
by: Locker Gottfried J, et al.
Published: (2006-03-01)

Sertoli-Leydig Cell Ovarian Tumors: Is Fertility or Endocrine-Sparing Surgery an Option upon Relapse?
by: Stéphanie J. Seidler, et al.
Published: (2020-07-01)

Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer
by: Ben O’Leary, et al.
Published: (2018-03-01)

Fulvestrant: Do not forget the history and opportunities for cost saving from real-world data
by: Amol Patel, et al.
Published: (2020-01-01)

Real-world data of fulvestrant as first-line treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer
by: I. Blancas, et al.
Published: (2021-02-01)

Combined treatment with everolimus and fulvestrant reversed anti-HER2 resistance in a patient with refractory advanced breast cancer: a case report
by: Sun B, et al.
Published: (2016-07-01)

Development and validation of a gene expression score that predicts response to fulvestrant in breast cancer patients.
by: Steen Knudsen, et al.
Published: (2014-01-01)

Sulfation of afimoxifene, endoxifen, raloxifene, and fulvestrant by the human cytosolic sulfotransferases (SULTs): A systematic analysis
by: Ying Hui, et al.
Published: (2015-07-01)